← Back to Clinical Trials
Recruiting NCT03378557

NCT03378557 Periprosthetic Fracture Registry (PPFx)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03378557
Status Recruiting
Phase
Sponsor AO Innovation Translation Center
Condition Periprosthetic Fractures
Study Type OBSERVATIONAL
Enrollment 600 participants
Start Date 2018-12-31
Primary Completion 2027-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 600 participants in total. It began in 2018-12-31 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This registry supports international data collection and research on PPFx treatments after hip and knee arthroplasty. A registry such as this ultimately aims to provide far-reaching benefits to society including reduced morbidity and mortality, improved patient safety, improved quality of care and medical decision-making, reduced medical spending, and advances in orthopaedic science.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Post-operative PPFx after total or hemi hip or total or unicondylar knee arthroplasty (including the acetabulum, femur, patella and proximal tibia) requiring * osteosynthesis alone or * component revision plus plate/nail osteosynthesis * Informed consent obtained, i.e.: * Ability of the patient or assigned representative to understand the content of the patient information / Informed Consent Form * Signed and dated EC / IRB approved written informed consent * Ability to attend post-operative follow up visits Exclusion Criteria: * Pregnancy or women planning to conceive within the study period * Prisoner

Contact & Investigator

Central Contact

Marco Minoia

✉ marco.minoia@aofoundation.org

📞 +41 79 612 09 67

Principal Investigator

Karl Stoffel, MD

PRINCIPAL INVESTIGATOR

Universitätsspital Basel

Frequently Asked Questions

Who can join the NCT03378557 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Periprosthetic Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03378557 currently recruiting?

Yes, NCT03378557 is actively recruiting participants. Contact the research team at marco.minoia@aofoundation.org for enrollment information.

Where is the NCT03378557 trial being conducted?

This trial is being conducted at Columbia, United States, Jersey City, United States, Livingston, United States, Nashville, United States and 9 additional locations.

Who is sponsoring the NCT03378557 clinical trial?

NCT03378557 is sponsored by AO Innovation Translation Center. The principal investigator is Karl Stoffel, MD at Universitätsspital Basel. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology